telos rx does not currently offer GHK-Cu for compounding. It is under internal review rather than part of the active program, and there is no confirmed date for when, or if, that status will change. This page explains exactly what that status means and why.
GHK-Cu is not part of the telos rx compounding program today. A 2026 regulatory review issued non-binding recommendations touching on several research peptides, GHK-Cu among them, but a recommendation is not approval. telos rx continues to review the substance rather than offer it, and there is no timeline to share.
What availability actually means here
Availability at telos rx has a specific meaning. It means a peptide has been formally added to the compounding program, and a partner pharmacy has confirmed it can prepare it consistently. A clinical review has also set guidance for who might be an appropriate candidate. GHK-Cu has not reached that point.
Being discussed online, being popular in longevity communities, or appearing in cosmetic products does not meet that bar. Those are different things entirely, and it helps to keep them separate when evaluating what a company actually offers versus what circulates in general conversation.
Why GHK-Cu specifically has not been added
Two things are true at once. The first is that GHK-Cu is a naturally occurring peptide with a long research history, mostly in laboratory and cosmetic contexts. The second is that a compounded, prescription-formulated version has not gone through the review telos rx requires before offering any peptide.
That review looks at sourcing, formulation consistency, and how a clinician should evaluate candidates. It is a deliberately conservative process, and GHK-Cu is simply still inside it rather than having failed it or been rejected.
Key takeaway: Under review is not the same as an imminent launch. There is no confirmed date, and treating GHK-Cu as available or in stock right now would be inaccurate.
The 2026 PCAC review, explained plainly
In 2026, the Peptide Compounding Advisory Committee reviewed a group of research peptides and issued recommendations regarding several of them, including GHK-Cu. Those recommendations were non-binding.
A non-binding recommendation carries weight in ongoing policy conversation. It does not change what a pharmacy is authorized to compound, and it does not obligate a telehealth company to add anything to its program. telos rx has treated the review as one input among several, not as a green light.
Online summaries of that review sometimes compressed this nuance into simpler, more optimistic language. If you read that GHK-Cu was cleared or approved somewhere, that framing overstates what actually happened.
How this differs from the TB-500 situation
It is worth contrasting GHK-Cu with a different case. TB-500 was classified by the FDA as a Category 2 bulk substance in late 2023, which restricts pharmacies from compounding it as a standalone product. telos rx offers a BPC-157 and TB-500 combination protocol as a separate, specifically reviewed offering, even though standalone TB-500 remains restricted.
GHK-Cu has not received a comparable classification in either direction. It sits in an ordinary internal review queue rather than a specific regulatory restriction, which is a different situation from TB-500's.
How telos rx decides what to add
Adding a peptide to the compounding program is not primarily a marketing decision. It depends on whether a partner pharmacy can reliably source and prepare a quality-controlled product. It also depends on whether there is enough clinical basis to set sensible guidance for a licensed provider to work from.
Both of those take time, and they are not driven by how much online interest a substance has generated. A peptide can be widely discussed and still not meet the bar for a responsible compounding program, and that gap is exactly where GHK-Cu currently sits.
What to watch for if the status changes
The clearest signal would be a dedicated page offering an actual evaluation, not simply more content discussing the peptide. This article and the page linked below will be updated if that happens.
Until then, be skeptical of any claim, from telos rx or elsewhere, suggesting GHK-Cu is in stock, on the way, or available with a specific date attached. None of that is accurate right now.
Why companies sometimes overstate this kind of status
There is a commercial incentive to sound more optimistic than the facts support. A company can generate traffic and interest by implying a popular peptide is nearly available, even when internal review has not concluded anything.
telos rx has chosen not to do that here. A plain, current no is less exciting than a teaser, but it is the accurate answer. It also avoids setting an expectation a reader might act on, such as delaying care while waiting for something with no confirmed arrival.
If you see another source describing GHK-Cu as newly available, verify that claim directly with the seller before assuming it reflects a real regulatory or clinical change. Marketing language and regulatory reality do not always move together.
Current status, stated one more time
telos rx does not currently offer GHK-Cu for compounding, full stop, with nothing implied about a near-term change. You can read more about telos rx's current status on GHK-Cu. That page, like this one, is informational rather than a place to begin treatment.
What internal review actually checks
A compounding review is not a single approval step. It covers several separate questions, and each one has to be answered before a peptide moves from research interest to an offered product.
Sourcing comes first. A partner pharmacy needs a reliable supplier of pharmaceutical-grade raw material, not a generic research chemical distributor. Formulation comes next, covering stability, appropriate concentration, and how the product should be stored and administered. Clinical guidance comes last, giving a provider a framework for evaluating who is and is not an appropriate candidate.
Each of those steps can stall independently. A peptide can have excellent research interest and still be held up on something as unglamorous as supply chain reliability. That is not a comment on GHK-Cu specifically, but it explains why review timelines are difficult to predict from the outside.
What this means for your own timeline
If you are making a near-term decision about your own health, it is worth not waiting on GHK-Cu specifically. There is no way to know today whether it will be added in the coming months, next year, or not at all.
A more productive approach is to identify the actual outcome you are hoping for, whether that is skin support, tissue recovery, or something else. Then ask a licensed provider what is realistically available now to address it. That conversation can happen immediately, regardless of what happens with GHK-Cu later.
Which is right for you
If you are looking to start a compounded peptide protocol today, telos rx currently offers BPC-157, PT-141, NAD+ nasal spray, and sermorelin. Each is reviewed and dispensed through partner compounding pharmacies after an asynchronous online visit.
If your interest in GHK-Cu was really about supporting recovery or tissue health, BPC-157 is the closest currently available option. Start a peptide evaluation to see what a clinician recommends.
How this page will be kept accurate
Regulatory status and internal review status can both shift over time. Rather than leave an old claim standing indefinitely, this page is treated as a living reference for telos rx's current position on GHK-Cu. Read it as reflecting the date it was last updated, not as a permanent, unchanging fact.
If you are reading this some time after publication, treat the linked GHK-Cu page as the primary source of truth. It reflects current status directly, rather than through a dated article.
Frequently Asked Questions
Does telos rx sell GHK-Cu right now?
No. GHK-Cu is under internal review and is not part of the active compounding program. There is no confirmed timeline for when, or if, that will change.
Is GHK-Cu banned or restricted like TB-500?
No. GHK-Cu has not received a specific FDA restriction the way TB-500 was classified. It is in an ordinary internal review process rather than a formal regulatory restriction.
What did the 2026 PCAC review actually decide about GHK-Cu?
It issued a non-binding recommendation, not approval. telos rx has not added GHK-Cu to its program based on that recommendation alone.
For how compounding is regulated more broadly, see the FDA's compounding overview.
Will GHK-Cu definitely be added eventually?
There is no way to say that with certainty. It depends on sourcing, formulation review, and clinical guidance coming together, and none of those steps follows a fixed or promised schedule.
How can I tell if the status has changed?
Check the GHK-Cu page directly. A dedicated evaluation offer, not just more written content, would be the real signal that something changed.
What can I do today if I want a compounded peptide?
telos rx currently offers BPC-157, PT-141, NAD+ nasal spray, and sermorelin. A licensed provider can help match one of those to your actual goal during an online visit.
For general context on skin biology relevant to some of these discussions, see the National Institute on Aging.
telos rx is LegitScript-certified. Compounded medications broadly are not FDA-approved, and GHK-Cu is not currently part of telos rx's compounding program. This article is general information, not medical advice, and does not replace guidance from your own provider. Approval for any treatment is subject to evaluation by a licensed provider, and approval is not guaranteed. Individual results vary. telos rx operates as an online-first, asynchronous telehealth service.
Curious what telos rx does offer today? Visit telos rx to see the current peptide lineup.